Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Objectives. We aimed at evaluating both the efficacy and safety of TJ-54 (Yokukansan) in patients with treatment-resistant schizophrenia. This randomized, multicenter, double-blind, placebo-controlled study was conducted. Methods. One hundred and twenty antipsychotic-treated inpatients were included...

Full description

Bibliographic Details
Main Authors:	Tsuyoshi Miyaoka, Motohide Furuya, Jun Horiguchi, Rei Wake, Sadayuki Hashioka, Masaya Thoyama, Kenta Murotani, Norio Mori, Yoshio Minabe, Masaomi Iyo, Shuichi Ueno, Sachiko Ezoe, Syuzo Hoshino, Haruo Seno
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Evidence-Based Complementary and Alternative Medicine
Online Access:	http://dx.doi.org/10.1155/2015/201592

Similar Items

Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study
by: Miyaoka Tsuyoshi, et al.
Published: (2012-11-01)

Yokukansan enhances the proliferation of B65 neuroblastoma
by: Yoshihiko Nakatani, et al.
Published: (2017-01-01)

Implications of Systemic Inflammation and Periodontitis for Major Depression
by: Sadayuki Hashioka, et al.
Published: (2018-07-01)

The Possible Causal Link of Periodontitis to Neuropsychiatric Disorders: More Than Psychosocial Mechanisms
by: Sadayuki Hashioka, et al.
Published: (2019-07-01)

Salivary Alpha-Amylase Activity Levels in Catatonic Schizophrenia Decrease after Electroconvulsive Therapy
by: Misako Kanayama, et al.
Published: (2018-01-01)

Yokukansan and its ingredients as possible treatment options for schizophrenia
by: Yu CH, et al.
Published: (2014-09-01)

Potential Application of Yokukansan as a Remedy for Parkinson’s Disease
by: Jung-Hee Jang, et al.
Published: (2018-01-01)

Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.
by: Toru Hiratsuka, et al.
Published: (2010-10-01)

Do Alzheimer's Disease Risk Gene Products Actually Act in Microglia?
by: Sadayuki Hashioka, et al.
Published: (2020-12-01)

The Effect of the Kampo Medicine Yokukansan on Preoperative Anxiety and Sedation Levels
by: Young-Chang Arai, et al.
Published: (2014-01-01)

Decreased Clostridium Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia
by: Misako Kanayama, et al.
Published: (2019-01-01)

Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model
by: Kenta Nakao, et al.
Published: (2019-01-01)

Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model
by: Liaury Kristian, et al.
Published: (2012-03-01)

Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
by: Takeyoshi K, et al.
Published: (2016-03-01)

Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report
by: Tsuyoshi Miyaoka, et al.
Published: (2017-09-01)

Corrigendum to “Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model”
by: Kenta Nakao, et al.
Published: (2019-01-01)

The Kampo Medicine Yokukansan Decreases MicroRNA-18 Expression and Recovers Glucocorticoid Receptors Protein Expression in the Hypothalamus of Stressed Mice
by: Shoko Shimizu, et al.
Published: (2015-01-01)

Kampo Formulations, Chotosan, and Yokukansan, for Dementia Therapy: Existing Clinical and Preclinical Evidence
by: Kinzo Matsumoto, et al.
Published: (2013-01-01)

Yokukansan, a Traditional Japanese Medicine, Adjusts Glutamate Signaling in Cultured Keratinocytes
by: Maki Wakabayashi, et al.
Published: (2014-01-01)

Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells
by: Kazushige Mizoguchi, et al.
Published: (2017-09-01)

Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study.
by: Hiroyuki Kitagawa, et al.
Published: (2015-01-01)

Antistress effects of Kampo medicine "Yokukansan" via regulation of orexin secretion
by: Katahira H, et al.
Published: (2017-03-01)

Antiallodynic Effect of Herbal Medicine Yokukansan on Peripheral Neuropathy in Rats with Chronic Constriction Injury
by: Yasuyuki Suzuki, et al.
Published: (2012-01-01)

Yokukansan and Yokukansankachimpihange Ameliorate Aggressive Behaviors in Rats with Cholinergic Degeneration in the Nucleus Basalis of Meynert
by: Masahiro Tabuchi, et al.
Published: (2017-04-01)

Inhibitory effect of the Kampo medicinal formula Yokukansan on acute stress-induced defecation in rats
by: Kanada Y, et al.
Published: (2018-04-01)

May Salivary Alpha-Amylase Level Be a Useful Tool for Assessment of the Severity of Schizophrenia and Evaluation of Therapy? A Case Report
by: Masa Ieda, et al.
Published: (2012-01-01)

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor
by: Sachiko Ezoe
Published: (2012-07-01)

Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan
by: Takashi Matsumoto, et al.
Published: (2018-12-01)

Yokukansan (Kampo medicinal formula) prevents the development of morphine tolerance by inhibiting the secretion of orexin A
by: Ayami Katayama, et al.
Published: (2018-06-01)

Effect of Yokukansan on sleep disturbance and neuropathic pain in chronic constriction injury using a rat model
by: Deguchi, R., et al.
Published: (2021)

Yokukansan Enhances Pentobarbital-Induced Sleep in Socially Isolated Mice: Possible Involvement of GABAA – Benzodiazepine Receptor Complex
by: Nobuaki Egashira, et al.
Published: (2011-01-01)

Inhibitory effect of yokukansan on the decrease in the hippocampal excitatory amino acid transporter EAAT2 in stress-maladaptive mice
by: Hiroko Miyagishi, et al.
Published: (2017-10-01)

Yokukansan Improves Mechanical Allodynia through the Regulation of Interleukin-6 Expression in the Spinal Cord in Mice with Neuropathic Pain
by: Shigeru Ebisawa, et al.
Published: (2015-01-01)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
by: Muneto Izuhara, et al.
Published: (2018-06-01)

Yokukansan, a Kampo medicine, enhances the level of neuronal lineage markers in differentiated P19 embryonic carcinoma cells
by: Makoto Fukui, et al.
Published: (2019-10-01)

The Kampo medicine Yokukansan (YKS) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells
by: Kazuki Terada, et al.
Published: (2018-08-01)

Yokukansan, a Traditional Japanese Medicine, Enhances the Glutamate Transporter GLT-1 Function in Cultured Rat Cortical Astrocytes
by: Toshiyuki Ueki, et al.
Published: (2018-01-01)

Potential Usefulness of the Kampo Medicine Yokukansan, Containing Uncaria Hook, for Paediatric Emotional and Behavioural Disorders: A Case Series
by: Yoshiyuki Tanaka, et al.
Published: (2013-01-01)

Yokukansan, a Kampo medicine, prevents the development of morphine tolerance through the inhibition of spinal glial cell activation in rats
by: Mariko Takemoto, et al.
Published: (2016-03-01)

Comparison of the Effects of Yokukansan and Yokukansankachimpihange on Glutamate Uptake by Cultured Astrocytes and Glutamate-Induced Excitotoxicity in Cultured PC12 Cells
by: Zenji Kawakami, et al.
Published: (2019-01-01)